Twist Bioscience reported Q1 fiscal 2026 revenue of $103.7 million, a 17% increase year-over-year from $88.7 million in Q1 2025. Management raised full-year revenue guidance to a range of $435 million to $440 million, up from the prior outlook of $420 million to $430 million. Growth was driven by increased adoption of synthetic DNA products in pharmaceutical research and industrial biotech applications, where order volumes rose 22% sequentially.

The company reiterated its target of achieving adjusted EBITDA breakeven in Q4 fiscal 2026, supported by operating expense discipline and efficiency gains in its manufacturing platform. Twist projects gross margin to exceed 52% for the full fiscal year, up from 49% in fiscal 2025, reflecting higher capacity utilization and cost reductions from its silicon-based synthesis technology. R&D spending remains elevated at 25% of revenue as the firm pursues next-generation enzyme engineering capabilities.

In Q1, Twist reported a GAAP net loss of $0.5 per share, compared with a loss of $0.53 per share in the year-ago quarter and a consensus estimate loss of $0.48. Operating cash flow improved to a $5 million outflow versus $12 million in Q1 2025, aided by tighter working capital management. The balance sheet remains solid, with $310 million in unrestricted cash and short-term investments as of December 31, 2025, sufficient to fund planned capital expenditures and R&D through the break-even point.